Skip to main content
Data show positive results for GI Dynamics' EndoBarrier device

Data from an investigator-initiated study showed GI Dynamics' EndoBarrier device demonstrated reductions in HbA1c levels and insulin usage without complications upon reimplantation for treatment of patients with obesity and type 2 diabetes. After the first explant, HbA1C levels fell from a baseline of 9.1% to 6.7% and insulin usage from 60iU to 19iU; with the second explant, HbA1C dropped from 7.8% to 7.1% and insulin usage from 33iU to 20iU.

Full Story: